Predicting Survival in Pulmonary Arterial Hypertension
Прогнозирование выживаемости при легочной артериальной гипертензии
2010-06-29
SCID: 54.1/vhhycusv
Discuss with AI
Cox proportional hazardsREVEAL Registryprognostic equationpulmonary arterial hypertensionsurvival prediction
Figures from the paper
Abstract (AI)
BACKGROUND: Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clinical use. METHODS AND RESULTS: Data from 2716 patients with PAH enrolled consecutively in the US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess predictors of 1-year survival. We identified independent prognosticators of survival and derived a multivariable, weighted risk formula for clinical use. One-year survival from the date of enrollment was 91.0% (95% confidence interval [CI], 89.9 to 92.1). In a multivariable analysis with Cox proportional hazards, variables independently associated with increased mortality included pulmonary vascular resistance >32 Wood units (hazard ratio [HR], 4.1; 95% CI, 2.0 to 8.3), PAH associated with portal hypertension (HR, 3.6; 95% CI, 2.4 to 5.4), modified New York Heart Association/World Health Organization functional class IV (HR, 3.1; 95% CI, 2.2 to 4.4), men >60 years of age (HR, 2.2; 95% CI, 1.6 to 3.0), and family history of PAH (HR, 2.2; 95% CI, 1.2 to 4.0). Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality. Based on these multivariable analyses, a prognostic equation was derived and validated by bootstrapping technique. CONCLUSIONS: We identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation. Use of this tool may allow the individualization and optimization of therapeutic strategies. Serial follow-up and reassessment are warranted. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00370214.
Key Findings
1
A REVEAL Registry cohort of 2,716 patients with pulmonary arterial hypertension was analyzed to identify predictors of 1-year survival.
2
Independent predictors of increased mortality included pulmonary vascular resistance >32 Wood units, portal-hypertension-associated PAH, functional class IV, male age >60 years, and family history of PAH.
3
Overall 1-year survival from enrollment was 91.0% (95% CI, 89.9–92.1).
4
Renal insufficiency, connective-tissue-disease-associated PAH, functional class III, hemodynamic measures, exercise capacity, biomarkers, diffusing capacity, and pericardial effusion also predicted mortality.
5
The study derived and bootstrap-validated a weighted prognostic equation intended to individualize treatment strategies, while emphasizing serial follow-up and reassessment.
Research Object
Patients with pulmonary arterial hypertension (PAH) enrolled in the US REVEAL registry
Research Subject
Predictors of 1-year survival and the multivariable prognostic risk relationship in PAH
Publication Details
Publication Date
2010-06-29
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest